162 related articles for article (PubMed ID: 33594944)
1. Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor.
Ferrari A; Bergamaschi L; Chiaravalli S; Pecori E; Diletto B; Alessandro O; Giandini T; Livellara V; Sironi G; Casanova M
Tumori; 2022 Feb; 108(1):93-97. PubMed ID: 33594944
[TBL] [Abstract][Full Text] [Related]
2. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.
Bisogno G; Ferrari A; Tagarelli A; Sorbara S; Chiaravalli S; Poli E; Scarzello G; De Corti F; Casanova M; Affinita MC
Pediatr Blood Cancer; 2021 Jul; 68(7):e28951. PubMed ID: 33694265
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
4. VIVA (vinorelbine, ifosfamide, vincristine, actinomycin-D): A new regimen in the armamentarium of systemic therapy for high-risk rhabdomyosarcoma.
Ferrari A; Chiaravalli S; Zecca M; Recupero S; Pascale S; Bergamaschi L; Casanova M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28649. PubMed ID: 32893953
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
6. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan and vincristine for the treatment of refractory desmoplastic small round cell tumor in a developing country: a case report.
Ambar NBD; de Seixas Alves MT; Lederman HM; Abib S; Duarte AAB; Caran EM
J Med Case Rep; 2019 Mar; 13(1):77. PubMed ID: 30851735
[TBL] [Abstract][Full Text] [Related]
9. An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy.
Bisogno G; Hawkins DS
Pediatr Blood Cancer; 2020 May; 67(5):e28174. PubMed ID: 31994316
[TBL] [Abstract][Full Text] [Related]
10. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Hua Q; Xu G; Zhao L; Zhang T
J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Bhatia S; Krailo MD; Chen Z; Burden L; Askin FB; Dickman PS; Grier HE; Link MP; Meyers PA; Perlman EJ; Rausen AR; Robison LL; Vietti TJ; Miser JS
Blood; 2007 Jan; 109(1):46-51. PubMed ID: 16985182
[TBL] [Abstract][Full Text] [Related]
12. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
13. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE
J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH
J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas.
Treuner J; Koscielniak E; Keim M
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S48-50. PubMed ID: 2667790
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
18. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
19. A 23-Year-Old Joradanian Woman with a Desmoplastic Small Round Cell Tumor Involving the Ovary.
Altal OF; Aleshawi AJ; Tashtush NA; Alhowary A
Am J Case Rep; 2019 Nov; 20():1675-1678. PubMed ID: 31723117
[TBL] [Abstract][Full Text] [Related]
20. Desmoplastic small round cell tumors in a young man.
Hirano G; Irie M; Nakashima Y; Shakado S; Sohda T; Tanaka T; Takamatsu Y; Aoki M; Tamura K; Nabeshima K; Sakisaka S
Intern Med; 2013; 52(17):1909-14. PubMed ID: 23994981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
